Optimer Pharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. have signed an exclusive two-year co-promotion agreement to market Dificid (fidaxomicin) in the U.S. Dificid is an antibiotic currently under review by the FDA for the treatment of Clostridium difficile infection (CDI), also known as Clostridium difficile-associated diarrhea (CDAD). The FDA is expected to complete its review by a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. Optimer will be responsible for the ...